DNB Carnegie lowers its fair value range for pharmaceutical company EQL Pharma to SEK 35–55, from SEK 35–60, ahead of the second quarter of 2026/27, according to commissioned research.
The research house expects revenue to increase 31 percent to SEK 113 million, supported by easier comparisons and rebuilt inventories. Adjusted EBIT is expected to come in at SEK 12 million, corresponding to a margin of 10 percent.
The forecast for adjusted EBIT is raised by 1 percent for 2026/27, but lowered by 3–4 percent for the following two years. The outlook for the second half is considered important for confidence in a sustained recovery.
